reason report
pharmedium rebound take time issu may
oper qualiti
bottom line remain confid core busi long-
term growth driver remain concern pharmedium busi
follow recent medacorp puls call believ take
least year win back pharmedium busi follow
challeng memphi facil neg surpris
hear two specialist state spend pharmedium
declin specialist turn in-sourc
compound busi use competitor pharmedium
posit side specialist highlight believ
fda concern process relat qualiti awar
re-cal contamin patient harm normal
compound facil open letter fda
manag forthright view time
take correct pharmedium divis becom tailwind
remain posit believ guidanc
clear event
pharmedium unlik win back busi price alon
compound transpar market price competit
call kol explain hospit tradit split
compound busi in-hous out-sourc facil
result hospit know input cost mark-up charg
outsourc facil price tend competit across
out-sourc vendor kol explain in-sourc cost
fraction extern out-sourc vendor charg hospit
capac constraint limit histor necessit use
outsourc compound vendor result believ unlik
win back busi pharmedium price alon one kol
claim would need discount price compel switch
volum back pharmedium
compound small portion total drug spend make
switch headach benefit neg
surpris hear one kol state spend pharmedium
declin past year highlight
stop busi pharmedium altogeth furthermor
compound drug modest portion hospit health system
total drug spend accord specialist call
annual compound drug repres small portion
total spend sound like kol want devot signific time
energi captur increment save compound drug
specialist indic in-sourc compound
work previous pharmedium turn
competitor difficult re-outsourc compound
net debt total capit
ep
estimate lt ep growth base
compani inform leerink partner llc research
revenu present billion dollar
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
almost compound facil issu
fda pharmedium challeng like quality-rel
pharmedium issu fda set compani apart
market accord one kol claim almost everi outsourc
compound facil current open letter fda
mani facil reportedli face issu qualiti pharmedium
problem label paper kol explain believ
issu contamin patient
affect somewhat concern mani compound
facil challeng fda past reliev
learn process-rel challeng somewhat routin
manag forthright suggest pharmedium becom
tailwind septemb met ceo steve colli
head ir bennett murphi mid-atlant bu tour
came away meet confid core busi
perform well like long-term growth driver
remain concern continu pharmedium headwind
lower ep estim result manag guid
memphi facil soon begin ship commerci becom
tailwind product memphi facil
pharmedium volum take time recov divis
becom tailwind believ compani success
win back lost busi
one pharmaceut distributor estim compani
captur pharmaceut distribut market term revenu
primari differenti distributor compani
focu specialti drug firm relationship estim
compani revenu deriv amerisourcebergen specialti group half
total revenu come oncology-rel busi come
drug compani non-specialti drug servic believ compani concentr
oncology-rel drug posit mani larg pend launch market
compani seem intens focu keep cost lean drive oper margin
expans watch measur everi basi point oper margin expans
quarterwhich view posit furthermor manag tend return signific
portion compani free cash flow back sharehold via common stock repurchas
dividend final abc relationship walgreen signific posit view sinc
walgreen own portion sinc walgreen use primari
distributor stand benefit wba growth market includ increment
volum result wba/ transact well increment volum
narrow network deal recent ink includ deal esrx/tricar optum
prime envis headwind exist includ competit sell-sid environ
on-going risk brand gener inflat rate presid trump potenti polici around
brand price unclear though believ ultim work industri despit
risk believ concern current reflect share price
increment revenu off-set mani headwind view given abc grow
market share seemingli decent brand inflat rate purchas power wbad growth
specialti market rate share outperform
puls call highlight challeng may face rebuild
recent host medacorp puls call two pharmaci kol discuss abc
beleagu pharmedium compound busi kol signific experi
pharmaceut compound hospit health system client
pharmedium past one current work larg academ medic center affili
larg nation health system work medium-s commun hospit
part three-hospit system overal convers suggest may face uphil
battl win back pharmedium custom either insourc
compound need switch anoth compound vendor follow shutdown
pharmedium largest plant memphi believ consist compani guidanc
win back lost busi suspect take time manag far
provid forthright realist comment around pharmedium view indic
turn-around rebuild effort take time becom tailwind
takeaway call includ follow
pharmedium struggl may paper issu qualiti issu unlik
problem face mani outsourc facil
almost outsourc facil still work issu uncov
fda inspect pharmedium alway good reput
price concess would signific much prompt hospit
switch back pharmedium order off-set inconveni chang outsourc
health system hospit tradit compound portion
compound pharmaceut product result know input cost therefor
high markup charg outsourc facil
one kol spend pharmedium annual three year ago
drop rel peak follow shutdown memphi plant
hospit maintain contract outsourc compound make
overal somewhat neg surpris feedback pharmedium custom
indic found sourc replac pharmedium sound like exist
hospit custom either in-sourc found new vendor replac pharmedium
difficult pharmedium win busi back despit challeng believ
manag forthright headwind amount time take
clear also believ manag well posit gain new potenti win
includ possibl expans express script
outsourc compound pharmaceut product
common transpar busi
compound pharmaceut product tradit split in-hous
compound out-sourc facil compound pharmaceut describ
one kol core function hospit signific piec pharmaceut drug
product administ patient inpati set product typic
deriv product order drug wholesal either dilut ad
medic alter way meet exact specif requir administr
accord kol tradit drug product made in-hous
cheaper allow hospit greater control product outsourc due
workload limit reduct wast longer shelf life product faster turn-around
time relat factor discuss kol sound like split in-
sourc out-sourc drug typic determin class drug pain
medic analges relat medic procur outsourc facil
abil in-sourc mean hospit know input cost mark-up charg
outsourc facil drug distribut consolid market big three distributor
op mp captur major market result hospit
insourc portion compound busi procur drug cost similar
outsourc facil result price transpar compound market high
kol call explain essenti know input cost mark-up
charg outsourc compound facil high level price transpar
discuss lead us believ price competit among outsourc facil leav littl
room pharmedium win back share base price alon
altern pharmedium exist necessarili
better feasibl hospit
almost outsourc facil issu fda accord one kol
pharmedium captur attent woe fda shutdown memphi
facil found interest one kol claim almost outsourc facil
previous continu work issu fda kol explain
facil open letter havent resolv sound us like issu
rang sever paperwork seriou inspect violat accord kol
hard find facil open letter view make challeng
pharmedium palat industri one sever vendor work
fda complaint lone compani avoid
pharmedium struggl may paper qualiti issu memphi plant
may back run variou facil open letter wide rang
violat accord one kol call pharmedium challeng memphi plant
character possibl paper issu rather qualiti issu face facil
kol explain heard pharmedium memphi facil
shutter due failur resolv issu flag previou year accord
one kol pharmedium found make product non-steril ingredi
requir sampl lot held back test ensur noth becom
contamin possibl pharmedium held test product lot
result fda want issu correct kol spoke
indic pharmedium may fail correct flaw process
contamin qualiti issu found paper issu process
improv assuag fda concern kol explain pharmedium may
correct issu could oper although neither knew exact statu one
explain plant oper back run within month
insourc cheaper viabl option requir complianc space
struggl overcrowd hospit insourc drug compound much cost
effect accord kol kol also explain often limit
much insourc hospit first much work exist staff
one kol explain increas product simpli ask fte perform work
obviou threshold anoth limit amount complianc space
steril meet variou requir drug compound hurdl
hospit press real-est howev one kol expand complianc space
within hospit pharmedium memphi facil shutdown allow kol
insourc compound drug use surgeri tradit outsourc
pharmedium may limit hospit one kol explain previou
convers save insourc substanti price reduct
case rel outsourc compound pharmaci could charg
pharmedium good reput outsourc compound pharmaci seen
commod kol agre pharmedium view
outsourc compound reput good benefici pharmedium kol
also character outsourc compound commod busi differ
vendor lone differ call slight differ total
number product offer compound
price concess would substanti win
busi back price alon
discount cite kol necessari win back busi import note
kol call compound drug product repres small portion
overal drug spend one kol annual compound drug spend
hospit total total drug spend compound repres small
portion overal drug spend kol explain would take larg discount price
compound drug get excit one kol explain unless offer
discount wouldnt consid worth time switch busi back
time energi analysi requir make switch wouldnt worth anoth
kol explain switch back pharmedium would reeduc nurs build
ndc code make sure bill streamlin accur short would
significantli compel financi caus kol switch back pharmedium
way win back custom honesti transpar given
appear minim opportun win back custom price alon ask kol
could actual win back busi pharmedium kol explain honest
frank messag market would go long way suggest detail happen
highlight product releas fail test lack
document slow address concern fda concern
qualiti safeti patient view light comment kol
issu face almost compound facil believ advic sound
believ patient harm think may take time win back new
busi believ pharmedium ultim abl re-right ship
kol histor maintain relationship
pharmedium drug distribut
kol relationship despit histori
work pharmedium interest hear call kol work
despit long histori work pharmedium
close acquisit pharmedium find interest despit relationship
mani year compound pharmaci kol switch core
kol report dissatisfact rep met need overal one kol
call process switch primari drug distributor
reason switch simpli standard across three-hospit system
work kol explain happi qualiti rep provid
despit low level expect distributor kol simpli want distributor
meet basic need suppli drug time correct amount happi
dissatisfact stem high turn-ov rate low qualiti cah rep cours
year kol report least differ rep rel inexperienc
may due fact work commun hospit may true
kol previous use year primari distributor report neutral
qualiti rate rep eight year explain difficult
identifi differ wholesal simpli big build buy drug
distributor work hard expand value-ad servic ancillari
solut kol appear ascrib much valu distributor offer outsid
core compet
align drug medic distribut one wholesal
conveni save discuss distributor ask one kol
use primari whether addit cost save synergi
get medic suppli drug one distributor kol explain greatest
benefit eas use familiar rather cost save kol
current use primari explain hospit get medic suppli
despit get drug less involv medic distribut
believ reason use decis ground servic rather
price commentari sound rel posit brand inflat compar prior year
gener deflat moder encourag hear one kol explain
believ inflat gener area consolid ration lead
price increas much isnt pervas kol believ
despit continu gener competit mani area price trend pretti flat price
stay pretti consist consist channel check includ
recent publish preview link price analysi brand side
kol explain believ littl chang price brand product
compar prior year normal continu year despit rhetor
washington view comment bode well pharma suppli chain
consist data
figur nadac price data highlight stabil gener deflat
im health leerink partner llc data august
overal somewhat surpris learn one kol volum pharmedium
annual three year ago drop sinc experienc issu
memphi plant specialist highlight year ago pay
pharmedium annual sinc complet dri gone zero
reduct spend sound signific us believ take least year
pharmedium recov quva sca pharma avella mention competitor
pharmedium one kol highlight quva breadth product capabl
improv substanti year howev one kol said couldnt imagin ever
purchas quva qualiti issu gener believ
take time pharmedium recov mis-step though encourag sound
like may signific contamin qualiti issu memphi facil rather
may process oper continu like believ
pharmedium becom tailwind also believ long-term mp
may acquir remina portion current own maintain op
rate
share trade ep estim behind
ntm price-to-earnings histor averag rel ep trade
trade view deserv premium
group mainli abc relationship transact believ new
client win posit renew comp eas higher oper cost allevi
trend gener deflat stabil next month expect
share trade ep would put stock
competit intens amerisourcebergen compet two larg drug distributor
competit among intens could lead
either posit neg earn revis furthermor chain independ
consolid usual one distributor retain contract exampl walgreen acquisit
duan read acquisit long unfavor impact
result larg billion dollar piec busi often chang
hand occurr happen past may happen futur
competit could also lead price eros medco health solut part esrx
repres revenu pre-wag top ten custom repres revenu
pre-wag custom lost could materi advers impact
earn share price custom face financi hardship
abil collect receiv could becom challeng insolv
supplier could also result advers impact financi result stock price
price economi impact earn result brand-
name manufactur buy-sid contract fee-for-servic ff arrang
inflat deflat brand-nam drug usual less impact earn rel
contract ff howev sinc price receiv custom often inflation-
base compon earn could unfavor impact addit economi weak
fewer peopl actual buy prescript drug due concern discretionari spend
lack health insur compani margin could come pressur
govern regul could advers impact compani pharmaceut
drug distribut industri highli regul state feder agenc includ
fda variou state board law pass may
pass futur intent increas safeti may like result higher cost
track trace chain custodi technolog also requir
hold valid state-level licens meet variou secur oper standard
failur compli feder state local law could advers impact compani
chang reimburs rate could impact earn effect januari
deficit reduct act dra chang feder upper limit
lowest publish price gener averag manufactur price
reform set less medicaid
improv patient provid act mippa delay adopt
make public least delay implement set
becom public reimburs compani retail custom come
pressur could advers impact firm sell-sid margin addit
reimburs rate chang awp awp roll back could
unfavor impact earn declin asp reimburs
medicar certain specialti drug could also advers impact result
compani revenu growth rate certain drug use oncolog come
pressur expand warn product safeti label nation coverag
decis could advers impact compani revenu growth rate
reform drug reimburs chang canada could also advers impact
compani earn power
chang due health reform could advers impact compani product
servic highli complex pervas throughout entir healthcar system
extens array reimburs mechan player within industri includ
manag care medicar medicaid pbm supplier materi chang
entiti health reform could impact margin
consolid competitor supplier custom purchas group could
advers impact compani earn
litig alway risk compani subject signific number healthcar law
includ fals claim act whistl blower act law relat sale purchas
pharmaceut product exampl offer remuner provid use certain drug
may illeg case
oper risk compani make acquisit risk integr could
caus cost rise oper issu occur addit compani embark cost
save program well streamlin process could result oper issu
data lost compani new implement program face challeng
could advers impact compani earn share price
implement compani enterpris resourc plan erp system could also
advers impact earn oper
incom statement model fiscal year end septemb mm
good sold
distribut sell administr
total revenu
total revenu
impair intang
amort intang
total revenu
total revenu
weight average number share
employe sever litig
